Justine Y. Bruce

Justine Y. Bruce

Oncology

600 Highland Ave
Madison, WI 53792

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

A Novel Syngeneic Mouse Model to Study Immune Evasion in Head and Neck Squamous Cell Carcinoma.

A Novel Syngeneic Mouse Model to Study Immune Evasion in Head and Neck Squamous Cell Carcinoma.

Journal: bioRxiv : the preprint server for biology

Published: August 01, 2026

Window-of-Opportunity Study Utilizing Preoperative Cetuximab in Patients with Head and Neck Cancer.

Window-of-Opportunity Study Utilizing Preoperative Cetuximab in Patients with Head and Neck Cancer.

Journal: Cancer research communications

Published: April 02, 2026

PEGylated IL2 and tumor-targeted radiotherapy augment CD8+ T cell-mediated anti-tumor response to anti-PD-1 in head and neck squamous cell carcinoma.

PEGylated IL2 and tumor-targeted radiotherapy augment CD8+ T cell-mediated anti-tumor response to anti-PD-1 in head and neck squamous cell carcinoma.

Journal: Theranostics

Published: March 28, 2026

Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9.

Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 24, 2025

Longitudinal Swallowing and Salivary Changes With CLR 131 and Re-Irradiation in Recurrent Head and Neck Cancer.

Longitudinal Swallowing and Salivary Changes With CLR 131 and Re-Irradiation in Recurrent Head and Neck Cancer.

Journal: Head & neck

Published: December 02, 2025

A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950).

A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950).

Journal: Cancer

Published: September 05, 2025

Immunotherapy in Head and Neck Cancer.

Immunotherapy in Head and Neck Cancer.

Journal: Cancer treatment and research

Published: August 23, 2025

Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: July 10, 2025

Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus.

Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 19, 2025

NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025.

NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 12, 2025

Axl Regulation of NK Cell Activity Creates an Immunosuppressive Tumor Immune Microenvironment in Head and Neck Cancer.

Axl Regulation of NK Cell Activity Creates an Immunosuppressive Tumor Immune Microenvironment in Head and Neck Cancer.

Journal: Cancers

Published: January 27, 2025

Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.

Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 31, 2024

Showing 1-12 of 52

Last Updated: 09/26/2026